Viking Therapeutics (NASDAQ:VKTX) rose 7.54% on June 23, 2026, as new institutional coverage renewed obesity drug interest, with shares closing at $34.81.

Key Highlights

  • Rose 7.54%: Viking Therapeutics closed at $34.81 on June 23 after moving $2.44 per share.
  • Catalyst: During the session, new institutional coverage renewed obesity drug interest.
  • Company: Viking Therapeutics develops treatments for obesity, metabolic disease and rare endocrine disorders.
  • Session: The stock finished at $34.81, while the available company record showed a disclosed catalyst for the move.

Viking Therapeutics (NASDAQ:VKTX) rose 7.54% on June 23, 2026, closing at $34.81 after a $2.44 per-share move. The session’s advance came as new institutional coverage renewed obesity drug interest, based on the available company disclosures and trading context.

Bullish analyst coverage, including a fresh Buy initiation with an $83 price target, and renewed enthusiasm around the obesity and metabolic disease therapeutic space supported the shares. Viking is advancing VK2735, a dual GIP/GLP-1 receptor agonist in both injectable and oral formulations, as well as VK0214 for X-linked adrenoleukodystrophy.

Viking Therapeutics develops treatments for obesity, metabolic disease and rare endocrine disorders.

No clinical data readout or regulatory filing was made during the June 23 session. The analyst initiation was the primary identifiable session catalyst.

The update concerned the development or regulatory path of a healthcare programme rather than a completed commercial launch. Clinical-stage milestones can include agency feedback, trial design, patient data or filing plans, each of which carries a different level of regulatory significance.

The shares closed at $34.81 after the market incorporated the disclosed programme information. The available record showed no additional approval decision during the June 23 session unless specifically stated in the company update.

For the June 23 close, the defining facts were the 7.54% advance, the $34.81 closing price and the catalyst described above. Any further change in the investment record would require a new filing, financial update, regulatory communication or transaction announcement from the company.